Patient-Focused Medical Product Development Webinar Series
There is growing interest in clinical outcome assessments, such as patient-reported outcomes, and patient-centeredness across the health care ecosystem. For example, in 2019, the Food and Drug Administration released two new guidance documents on clinical outcome assessment. The NHC seeks to ensure that the NHC membership is prepared to engage in conversations about clinical outcome assessment.
Patient-Focused Medical Product Development Webinar Series: A Look at Rare Disease Listening Sessions with NORD and the FDA
Jan. 31, 1 p.m. ET
Our first webinar of 2020 will feature Debbie Drell, Director of Membership, at the National Organization for Rare Diseases (NORD), and Andrea Furia-Helms, Director, Patient Affairs Staff at Food and Drug Administration (FDA) to discuss their collaboration on Rare Disease Patient Listening Sessions. The listening sessions are facilitated by FDA Patient Affairs Staff and offer patients and caregivers an opportunity to speak directly to FDA staff about what it’s like to live with a specific rare disease. The sessions help FDA staff understand the patients’ perspective about their disease, needed treatment options, and meaningful outcomes. Register here.
What is the Difference Between Health-Related Quality of Life (HRQoL) and Patient-Reported Outcomes?June 10, 2019 Read More
Measuring Patient Experiences: Distinguishing Between Patient-Reported Outcomes and Patient PreferencesApril 18, 2019 Read More
If you would like to suggest a topic, please submit one below.
Sponsors include: Pfizer